Adenosine Monophosphate for Injection
Function and Efficacy
This product is an anti-deoxyribonucleic acid (DNA) virus drug. Its pharmacological action is to bind to the viral deoxyribonucleic acid polymerase, reduce its activity and inhibit DNA synthesis. After entering the cell, adenosine monophosphate is phosphorylated to generate adenosine diphosphate (Ara-ADP) and adenosine triphosphate (Ara-ATP). The antiviral activity is mainly caused by adenosine triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, allowing Ara-A to penetrate into the viral DNA and connect to the end of the DNA chain at the 3′-OH position, inhibiting the continued synthesis of viral DNA.
Ingredients
The main ingredient of this product is adenosine monophosphate.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Vidarabine monophosphateIngredients |
It binds to the viral DNA polymerase, reducing its activity and inhibiting DNA synthesis. After phosphorylation, it generates adenosine arabinoside diphosphate (Ara-ADP) and adenosine arabinoside triphosphate (Ara-ATP). Ara-ATP and deoxyadenosine triphosphate (dATP) compete to bind to viral DNAP, thereby inhibiting the activity of the enzyme and the synthesis of viral DNA. At the same time, it inhibits the activity of viral nucleotide reductase and inhibits the synthesis of viral DNA. It can also inhibit the activity of viral DNA terminal deoxynucleotidyl transferase, allowing Ara-A to penetrate into the viral DNA and connect to the end of the DNA chain at the 3′-OH position, inhibiting the continued synthesis of viral DNA. More |
29984-33-6 | 12 |
Appearance
This product is white or off-white freeze-dried sterilized powder.
Indication
Used to treat stomatitis, dermatitis, encephalitis and cytomegalovirus infection caused by herpes virus infection.
Usage and Dosage
Before use, add 2 ml of sterile saline to each bottle and dissolve it, then inject it intramuscularly or slowly intravenously, or follow the doctor's advice. For adults, take 5-10 mg/kg per day according to body weight. Pay close attention to the occurrence of adverse reactions during medication and deal with them in time.
Adverse Reactions
Pain at the injection site may be seen. In rare cases, neuromuscular pain and joint pain may occur, and thrombocytopenia, leukopenia or bone marrow giant cell hyperplasia may occasionally occur, which can recover on their own after discontinuation of the drug and are reversible. Symptomatic treatment can be used if necessary. The degree of adverse reactions is positively correlated with the dosage and course of treatment.
Precautions
Not yet clear
Special Population Medication
Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference. Precautions for the elderly: This experiment has not been conducted and there is no reliable reference.
Drug Interactions
It should not be used with calcium-containing infusions. It should not be used with blood, plasma and protein infusions. Allopurinol can increase the toxicity of this product to the nervous system and it should not be used with allopurinol. Using it with interferon can aggravate adverse reactions.
Storage
Keep away from light and store in a sealed container.
Packaging Specification
0.1 g
Validity Period
24 months
Manufacturer
Jilin Aodong--Taonan Pharnalentical Company Ltd
-
Founded in:
1998-02-06 -
Address:
No. 2999, Xingye Road, Taonan Economic Development Zone, Jilin Province -
Tax NO.:
912208007022438244 -
Registered Funds:
70.170757 million yuan -
Website:
-
Email: